Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 3Genitourinary 2Thoracic 1Other 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 107Triple Negative Breast Neoplasms 15Neoplasm Metastasis 14Carcinoma, Renal Cell 6Breast Neoplasms, Male 6Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Recurrence 2Breast Diseases 2Advanced Breast Cancer 2Unilateral Breast Neoplasms 1Thrombocytosis 1Somatostatinoma 1Skin Diseases 1Prostatic Neoplasms 1Primary Non-metastatic Breast Cancer 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mucositis 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Trastuzumab 2tipifarnib 1Interleukin-12 Subunit p35 1Interleukin-12 1Fentanyl 1Everolimus 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrinoma × Everolimus × Breast × Clear all
NCT02273752 2017-02-03

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Emory University

Phase 2 Terminated
2 enrolled 5 charts
BreastEndocrineGenitourinaryOther

Breast Neoplasms, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡